Atlantis Healthcare Patient Support Programs Shortlisted For PMEA Awards 2016
LONDON, Oct. 10, 2016 /PRNewswire/ -- Atlantis Healthcare, a global leader in patient self-management and health behavior change, announces today that it will be a finalist for the prestigious Pharmaceutical Market Excellence Awards (PMEA) awards, to be held in London on 23 November 2016.
Logo - http://photos.prnewswire.com/prnh/20160518/369636LOGO
Atlantis is shortlisted for two awards for its patient solutions, including 'Life After Heart Attack' (LAHA) in acute coronary syndrome (ACS) and 'Let's Talk Tyrosinaemia' in hereditary type 1 tyrosinaemia (HT-1). These multi-market initiatives have been designed and run in partnership with AstraZeneca Plc (AZ) and the Swedish Orphan Biovitrum AB (Sobi) groups, respectively.
About 'LAHA'
LAHA is a free, multi-channel support program developed by Atlantis and AZ for patients with ACS in the United Arab Emirates. ACS is a set of life-threatening heart conditions including heart attack and unstable angina, for which patients take a range of medications. LAHA is designed to improve adherence levels, which are typically poor in this patient group, despite the potential consequences of increased risk of heart attack and death. The program has positively impacted treatment persistence (99% at three months; 95% at six months and 83% at 12 months post-enrolment), patient beliefs and lifestyle changes.
About 'Let's Talk Tyrosinaemia'
Let's Talk Tyrosinaemia is a global suite of free support tools developed by Atlantis and Sobi for HT-1 families and healthcare professionals (HCPs). HT-1 is an ultra-rare genetic disorder in which symptoms often manifest within the first few months of life. Left untreated it can lead to serious health problems, and children often do not survive past the age of 10. Previously, little was known about the self-management needs of families living with HT-1, with a paucity of high-quality information and support leaving families feeling isolated, unsupported and underinformed.
Qualitative and quantitative research conducted by Atlantis highlighted adherence barriers to a low-tyrosine diet and medication. This research was published in the Journal of Inherited Metabolic Disease. Let's Talk Tyrosinaemia was co-created with clinical psychologists, specialist nurses, dietitians and carers to provide practical and psychoeducational support. Comprehensive guides were designed to empower and support HT-1 families and HCPs to optimally manage the disease and to address adherence barriers. The program has been implemented in UK, France, Spain, Italy, Germany and USA and has received unprecedented feedback from families and HCPs alike.
Matthew Walls, Chairman and CEO of Atlantis said: "We are delighted to be in the final of the PMEA awards for our ACS and HT-1 programs. Patient self-management of chronic illness demands scalable programs that enable the patient to take greater responsibility for their own healthcare to help improve health outcomes".
"We are proud that our programs continue to gain recognition by helping patients better self-manage their health. This is achieved by promoting a combination of overt behavioral actions – including motivation, physical activity and better eating habits – alongside traditional medication adherence. With the advance of biologics and specialty treatments, Atlantis Healthcare's unique self-management framework ensures the best program support available to meet patients' needs".
To download more information about Atlantis Healthcare's approach to delivering best-in-class self-management solutions, visit:
http://www.atlantishealthcare.com/uk/approach
For further details on Atlantis Healthcare Group please contact:
Matthew Walls: Chief Executive Officer +44 208 747 4360
About Atlantis Healthcare Group
Atlantis Healthcare is the expert in the design, development and delivery of scalable global, multi-channel patient support solutions which drive sustained improvements in patient self-management and improved health outcome. By applying the Atlantis self-management behavior-change model, Atlantis delivers personalized patient programs to address an individual's barriers to self-management and adherence to positively impact patients' treatment outcomes and experience.
With the largest team of globally recognized health psychology experts working in collaboration with creative and digital product experts, Atlantis uses clinically proven models and academic research to develop award-winning behavior change programs, helping patients achieve better health outcomes. The group provides products and services across the globe from offices in Australia, Germany, New Zealand, Spain, UK and the US.
Share this article